Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects With Palmoplantar Pustulosis

NCT03988335 is registered in ClinicalTrials.gov with Aristea Therapeutics, Inc. as lead sponsor.

NCT NCT03988335
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03988335 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects With Palmoplantar Pustulosis
Lead sponsor
Aristea Therapeutics, Inc.
Phase
Phase 2
Overall status
Completed
Start date
February 13, 2019
Completion date
November 19, 2019
Enrollment
35 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

palmoplantar pustulosis